GIMM

GIMM Fest, in one word. We asked the people who experienced it to sum it up in just one word. These were their answers. 🦠 What would your word be?

Three days of science, questions, conversations and plenty of curious minds. 🧫✨ And now, it’s time to say goodbye, in many different languages, but with the same message: See you next year! 👋 Thank you to everyone who made GIMM Fest 2026 so special. Until next time! 🦠

Three days. Countless questions. So many moments to remember. 🦠 From inspiring talks to hands-on activities and lively conversations, GIMM Fest 2026 brought science closer to everyone. Thank you to our speakers, guests, partners, volunteers and everyone who joined us and made these three days so special. Until the next chapter. ✨

That’s a wrap on the scientific programme! 🦠 A huge thank you to all the speakers, guests and partners who joined us for two days filled with science, questions and inspiring conversations. And as we look ahead… GIMM Fest 2027 will be all about Synthetic Biology. 🧬 But GIMM Fest isn’t over yet! Tomorrow, we’re opening the doors for a day of science, discovery and fun for everyone. 🧫

GIMM researcher Miguel Prudencio and his team have just published a study in The Journal of Infectious Diseases exploring a new strategy against malaria that combines infection treatment with the development of long-lasting immunity. The study investigates the potential of cabamiquine (CBQ), a new antimalarial drug that can control the infection while maintaining sufficient exposure to the parasite for the immune system to develop immune memory, without allowing the infection to progress to severe disease. Tested in mouse models of malaria, this “infection-and-treatment” strategy successfully cleared the initial infection and protected the animals when they were subsequently exposed to the parasite again. These findings point to a promising approach that could turn the treatment of an infection into an opportunity to prepare the immune system for future infections, creating a potential bridge between treatment and vaccination. Find out more: https://lnkd.in/egvy-CDf -- O investigador Miguel Prudencio e a sua equipa no GIMM acabam de publicar, na revista The Journal of Infectious Diseases, um estudo que explora uma nova estratégia contra a malária, combinando o tratamento da infeção com o desenvolvimento de imunidade duradoura. A investigação avalia o potencial da cabamiquina (CBQ), um novo antimalárico capaz de controlar a infeção, mantendo ao mesmo tempo uma exposição suficiente ao parasita para permitir ao sistema imunitário desenvolver memória imunitária, sem que a infeção evolua para doença grave. Testada em modelos de malária em ratinhos, esta estratégia de “infeção e tratamento” conseguiu eliminar a infeção inicial e proteger os animais quando foram novamente expostos ao parasita. Estes resultados apontam para uma abordagem promissora que poderá transformar o tratamento de uma infeção numa oportunidade para preparar o sistema imunitário para futuras infeções, criando uma potencial ponte entre tratamento e vacinação. Saiba mais: https://lnkd.in/egvy-CDf

From inspiring talks to thought-provoking discussions, GIMM Fest brings together science, ideas and people to explore the questions that matter most. Join the conversation. 👉 Register now at the link in comments. European Research Executive Agency (REA) EU Science, Research and Innovation